(4R,5S)-5-(1,5-dimethylpyrazol-4-yl)-4-[[(E)-3-(furan-2-yl)prop-2-enyl]amino]-1-methylpyrrolidin-2-one
C17H22N4O2 — CID 129005139
Data last refreshed: (MolForge compound catalog, from PubChem)
About (4R,5S)-5-(1,5-dimethylpyrazol-4-yl)-4-[[(E)-3-(furan-2-yl)prop-2-enyl]amino]-1-methylpyrrolidin-2-one
(4R,5S)-5-(1,5-dimethylpyrazol-4-yl)-4-[[(E)-3-(furan-2-yl)prop-2-enyl]amino]-1-methylpyrrolidin-2-one (PubChem CID 129005139) has the molecular formula C17H22N4O2 and a molecular weight of 314.39 g/mol. Its IUPAC name is (4R,5S)-5-(1,5-dimethylpyrazol-4-yl)-4-[[(E)-3-(furan-2-yl)prop-2-enyl]amino]-1-methylpyrrolidin-2-one.
Molecular Properties
| Compound Name | (4R,5S)-5-(1,5-dimethylpyrazol-4-yl)-4-[[(E)-3-(furan-2-yl)prop-2-enyl]amino]-1-methylpyrrolidin-2-one |
|---|---|
| PubChem CID | 129005139 |
| Molecular Formula | C17H22N4O2 |
| Molecular Weight | 314.39 g/mol |
| Exact Mass | 314.17 |
| IUPAC Name | (4R,5S)-5-(1,5-dimethylpyrazol-4-yl)-4-[[(E)-3-(furan-2-yl)prop-2-enyl]amino]-1-methylpyrrolidin-2-one |
| SMILES | Cc1c([C@H]2[C@H](NC/C=C/c3ccco3)CC(=O)N2C)cnn1C |
| InChI | InChI=1S/C17H22N4O2/c1-12-14(11-19-21(12)3)17-15(10-16(22)20(17)2)18-8-4-6-13-7-5-9-23-13/h4-7,9,11,15,17-18H,8,10H2,1-3H3/b6-4+/t15-,17+/m1/s1 |
| InChIKey | KOGBKFRRPGXKMA-UXILZDJPSA-N |
| XLogP | 1.90 |
| TPSA | 63.30 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 23 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 314.39 |
| LogP ≤ 5 | 1.90 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 129005139 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.